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Objective: The aim of these studies (NCT01957163; NCT02119286) was to evaluate the efﬁcacy and safety
of umeclidinium (UMEC 62.5 mg and 125 mg) added to ﬂuticasone furoate/vilanterol (FF/VI, 100/25 mg) in
chronic obstructive pulmonary disease (COPD).
Methods: These were 12-week, double-blind, placebo-controlled, parallel-group, multicenter studies.
Eligible patients were randomized 1:1:1 to treatment with once-daily blinded UMEC 62.5 mg (delivering
55 mg), UMEC 125 mg (delivering 113 mg) or placebo (PBO) added to open-label FF/VI (delivering 92/22 mg;
N ¼ 1238 [intent-to-treat population]). The primary endpoint was trough forced expiratory volume in
one second (FEV1) on Day 85; the secondary endpoint was 0e6 h post-dose weighted mean (WM) FEV1
at Day 84. Health-related quality of life was reported using St George's respiratory questionnaire (SGRQ).
Adverse events (AEs) were also assessed.
Results: In both studies, trough FEV1 was signiﬁcantly improved with UMEC þ FF/VI (62.5 mg and 125 mg)
versus PBO þ FF/VI (range: 0.111e0.128 L, all p < 0.001 [Day 85]), as was 0e6 h post-dose WM FEV1
(range: 0.135e0.153 L, all p < 0.001 [Day 84]). SGRQ results were inconsistent, with statistically signif-
icant improvements with UMEC þ FF/VI versus PBO þ FF/VI in one study only and with UMEC 62.5 mg
only (difference in SGRQ total score from baseline between treatments: 2.16, p < 0.05). Across all
treatment groups, the overall incidences of AEs were similar (30e39%), as were cardiovascular AEs of
special interest (<1e3%) and pneumonia AEs (0e1%).
Conclusion: Overall, the addition of UMEC to FF/VI therapy resulted in signiﬁcant improvements in lung
function compared with PBO þ FF/VI in patients with COPD, with similar safety proﬁles, though SGRQ
results were inconsistent.
Clinical relevance: The results from these two studies demonstrate that the addition of umeclidinium
(62.5 mg and 125 mg) to FF/VI (100/25 mg) provides statistically signiﬁcant and clinically meaningful
improvements in lung function compared with placebo þ FF/VI in patients with COPD. Statistically
signiﬁcant improvements in quality of life with UMEC þ FF/VI versus placebo þ FF/VI were reported in
one study only. Safety proﬁles were consistent across all treatment groups in both studies. These studies
support the use of triple therapy in COPD, providing physicians with an alternative treatment option.
© 2015 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).s enrolled; CAT, COPD Assessment Test; CI, conﬁdence interval; COPD, chronic obstructive pulmonary disease; FEV1,
ne furoate; FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease; HRQoL, health-
intent-to-treat; LABA, long-acting beta2 agonist; LAMA, Long-acting muscarinic antagonist; LS, least squares; MedDRA,
cebo; PRO, patient-reported outcome; QoL, quality of life; RI, run-in; SAE, serious adverse event; SGRQ, St George's
vilanterol; WM, weighted mean.
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Chronic obstructive pulmonary disease (COPD) is characterized
by persistent airﬂow limitation, is a substantial contributor to
morbidity and mortality worldwide, and imparts a high economic
burden [1,2]. Central to the pharmacological management of COPD
are inhaled bronchodilators, such as muscarinic antagonists and
beta2-agonists [1] and inhaled anti-inﬂammatory agents, such as
corticosteroids [1].
As disease severity increases, COPD treatment guidelines
recommend an incremental approach to pharmacological treat-
ment, involving the use of combinations of drug classes with
different or complementary mechanisms of action [1,3]. Long-
acting muscarinic antagonists (LAMAs) have been shown to
improve lung function, relieve symptoms, increase exercise ca-
pacity, improve quality of life (QoL) and reduce COPD exacerbations
to a greater extent than short-acting bronchodilators alone [1,4,5].
Inhaled corticosteroid (ICS)/long-acting beta2 agonist (LABA)
combination products have been shown to improve lung function,
health status and reduce COPD exacerbations compared with either
agent alone [1].
The use of combinations of drug classes with complementary
mechanisms of action addresses the multi-component, inﬂamma-
tory and progressive nature of COPD [1]. Recent studies involving
the LAMA tiotropium in patients with COPD have shown that the
addition of a LAMA to an ICS/LABA combination was well tolerated
and associatedwith improvements in pulmonary, symptomatic and
health-related QoL (HRQoL) endpoints [6e10]. Based on the results
of several trials, the Global Initiative for Chronic Obstructive Lung
Disease (GOLD) guidelines now include a recommendation for the
use of a LAMA plus an ICS/LABA product as a secondary treatment
option for symptomatic COPDwith severe airﬂowobstruction and a
high risk of exacerbations [1].
Although guidelines recommend a LAMA plus ICS/LABA as a
treatment for patients with very severe COPD, physician prescrib-
ing practices differ from treatment guidelines, which may reﬂect
differences in clinical judgement of the severity of COPD disease. In
one study that examined the GOLD strategy in a real-world COPD
population, 22.2% of patients categorized as having moderate COPD
(according to the GOLD 2010 and 2011 criteria) received treatment
with a LAMA plus an ICS/LABA, whereas 58.4% of patients with very
severe COPD received a LAMA plus an ICS/LABA [11].
Umeclidinium bromide 62.5 mg (UMEC, GSK573719; GSK, Lon-
don, UK) is a LAMA indicated for the treatment of COPD [4,12].
Fluticasone furoate/vilanterol (FF/VI) is a once-daily ICS/LABA
combination indicated for the treatment of patients with COPD
[13]. Here, we present the results of two clinical studies investi-
gating the efﬁcacy and safety of once-daily UMEC (62.5 mg and
125 mg) in addition to once-daily FF/VI (100/25 mg) in patients with
moderate-to-very-severe COPD.
2. Materials and methods
2.1. Study designs
Two replicate, 12-week, randomized, double-blind, placebo-
controlled parallel-group studies were completed between October
2013 and April 2014. Study 1 (ClinicalTrials.gov registration num-
ber: NCT01957163; GSK study number: 200109) was conducted in
Argentina, Canada, Chile, Romania and the USA. Study 2 (Clinical-
Trials.gov registration number: NCT02119286; GSK study number:
200110) was conducted in the Czech Republic, Germany, the Re-
public of Korea and the USA. Both studies were conducted in
accordance with the Declaration of Helsinki [14] and Good Clinical
Practice guidelines, were approved by the relevant local ethicsreview committees, and all patients provided written, informed
consent before study participation.
2.2. Patients
Eligible patients were: 40 years of age with a clinically
established history of COPD [3]; current or former cigarette
smokers with 10-pack-years smoking history; had a pre- and
post-salbutamol (albuterol) forced expiratory volume in one sec-
ond (FEV1)/forced vital capacity (FVC) ratio of <0.7 and predicted
FEV1 70%; and had a modiﬁed Medical Research Council dyspnea
scale score 2. Exclusion criteria included: current diagnosis of
asthma or other known respiratory disease, hospitalization in the
12 weeks previous to Visit 1 for COPD or pneumonia, pregnancy, or
use of long-term oxygen therapy. Patients previously receiving
COPD medications were eligible provided they adhered to the
following exclusion periods prior to Visit 1 and subsequently
avoided their use throughout the study: ICS use was permitted to
Visit 1, LAMA use required a 7-day exclusion period and the use of
ICS/LABA combination therapies required a 48-h exclusion period
(further details of inclusion/exclusion criteria, permitted/pro-
hibited medications and washout periods are provided in
Supplementary Materials).
2.3. Treatment
Following screening at Visit 1, patients underwent 4 weeks' run-
in treatment with open-label FF/VI 100/25 mg (delivering 92/22 mg)
prior to the 12-week treatment period (Visits 2e7). Eligible patients
were randomized 1:1:1e12 weeks' treatment with once-daily
UMEC 62.5 mg (delivering 55 mg), UMEC 125 mg (delivering
113 mg), or placebo (PBO), plus FF/VI (100/25 mg once daily)
administered via the ELLIPTA™ dry powder inhaler. UMEC and PBO
treatments were double-blind; FF/VI treatment was open label.
Randomization codes were generated by GSK using a validated
computerized system (RandAll v2.13). Concurrent use of
salbutamol as rescue medication was permitted throughout the
study, except during the 4 h prior to spirometry testing.
2.4. Outcomes and assessments
In both studies, the primary efﬁcacy endpoint was trough FEV1
at Day 85 (deﬁned as the mean of the FEV1 values obtained 23 and
24 h after dosing on Day 84). An increase of 0.100 L was considered
as the minimal clinically important difference (MCID) for this
endpoint [15,16]. The secondary efﬁcacy endpoint was weighted-
mean (WM) FEV1 over 0e6 h obtained post-dose on Day 84.
Other lung function endpoints included: proportion of patients
achieving an increase of 0.100 L above baseline in trough FEV1;
lung function endpoints (trough FEV1 and WM FEV1 over 0e6 h
post-dose) at other timepoints; the proportion of patients
achieving an increase in FEV1 of 12% and 0.200 L above baseline
at any time during 0e6 h post-dose at Day 1; serial FEV1 over 0e6 h
(at each timepoint); peak FEV1 at Days 1, 28 and 84; time to onset of
treatment response (deﬁned as an increase of 0.100 L above base-
line in FEV1 [not speciﬁed in the original protocol]); and serial and
trough FVC at each timepoint.
Other endpoints included rescue medication, as assessed by the
percentage of rescue-free days and puffs/day (descriptive data
only). HRQoL endpoints included the COPD Assessment Test (CAT;
descriptive data only) [17,18] and St George's Respiratory Ques-
tionnaire for COPD Patients (SGRQ-C) [19]. SGRQ scores were
calculated from the SGRQ-C-scores using standardized adjustment.
Safety assessments included adverse events (AEs), vital signs
(including pulse rate and systolic and diastolic blood pressure) and
T.M. Siler et al. / Respiratory Medicine 109 (2015) 1155e1163 1157COPD exacerbations. Patients were withdrawn if they experienced
a COPD exacerbation during the run-in or treatment periods. COPD
exacerbations were deﬁned as an acute worsening of symptoms
requiring the use of any treatment beyond study medication or
rescue salbutamol. AEs of special interest included cardiovascular
events, pneumonia and lower respiratory tract infections.
2.4.1. Sample size considerations and statistical analyses
Sample size calculations were based on the primary endpoint of
trough FEV1 at Day 85. They assumed 90% power and a 2-sided 5%
signiﬁcance level with an estimate of residual standard deviation
for trough FEV1 of 0.220 L and a treatment difference of 0.080 L.
According to these assumptions, and to account for an estimated
withdrawal rate of 20%, 160 patients per arm (480 in total for each
study) were required for 90% power to detect a 0.080 L difference
between treatments in trough FEV1.
The primary efﬁcacy analysis population was the intent-to-treat
(ITT) population, deﬁned as all patients randomized to treatment
who received at least one dose of study drug. Primary and sec-
ondary endpoints were analyzed using mixed models repeated
measures analysis, with treatment, baseline FEV1, smoking status,
and day as covariates. Day-by-baseline and day-by-treatment were
included as interactions. To account for multiplicity, a step-down
closed testing hierarchy was employed (See Supplementary
Materials), as reported previously [20]. The safety population
comprised all patients enrolled in the study, though on-treatment
AEs were assessed using the ITT population.
3. Results
3.1. Patients
Study 1 enrolled 727 patients across 55 centers; 26% of patients
were enrolled in the USA, 21% in Chile, 20% in Canada, 17% in
Romania and 16% in Argentina. Following screening, 619 patientsFig. 1. Patient disposition in Study 1 (a) and in Study 2 (b). ASE, all subjects enrolled; COP
nation; RI, run-in; UMEC, umeclidinium. *Lack of efﬁcacy contains patients who withdrewwere randomized and included in the ITT population and 575 (93%)
patients completed the study (Fig. 1A). Study 2 enrolled 730 pa-
tients across 59 centers; 46% of patients were enrolled in study
centers in Germany, 29% in the USA, 14% in the Czech Republic and
11% in the Republic of Korea. Of the 730 patients enrolled, 620 were
randomized, 619 included in the ITT population and 575 (93%)
completed Study 2 (Fig. 1B).
Baseline characteristics are summarized in Table 1. Overall, the
only differences were that Study 2 enrolled more current smokers
than Study 1 (56e58% and 39e44% across treatment groups,
respectively) and the two studies had different proportions of
patients at GOLD lung function stages II and III (stage II: Study 1:
40e41%, Study 2: 46e50%; stage III, Study 1: 44e48%, Study 2:
40e42%). No other differences were identiﬁed between studies or
between treatment groups within each study (Table 1). Across
both studies 10e17% of patients were classiﬁed as having very
severe COPD (GOLD stage IV) (Table 1). Across treatment groups,
25e32% of patients were reversible to salbutamol (deﬁned as
an increase in FEV1 of 12% and 0.200 L following treat-
ment administration) and 39e53% reversible to salbutamol plus
ipratropium (Table 1).
Prior to enrollment in Study 1, 63% of patients were receiving
treatment with an ICS, 61% were receiving a LABA, and 22% were
receiving a LAMA. In Study 2, the percentage of patients with prior
use of an ICS was 46%, LABA 62%, and LAMA 46%. In the 12 months
before screening, the majority of patients reported no COPD exac-
erbations that required treatment with oral/systemic corticoste-
roids and/or antibiotics (Study 1: 85% and Study 2: 86%).
3.2. Outcomes
3.2.1. Lung function
In both studies, addition of UMEC to FF/VI resulted in statisti-
cally signiﬁcant and clinically meaningful improvements in trough
FEV1 at Day 85 versus PBO þ FF/VI (UMEC 62.5 mg þ FF/VI,D, chronic obstructive pulmonary disease; FF/VI, ﬂuticasone furoate/vilanterol combi-
due to COPD exacerbation.
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Table 2; Fig. 2). Statistically signiﬁcant improvements with
UMEC þ FF/VI versus PBO þ FF/VI were also observed for trough
FEV1 at Days 2, 28, 56 and 84 (p < 0.001, for both doses at each
timepoint in both studies; Fig. 2).
For the secondary endpoint of 0e6 h post-dose WM FEV1 at
Day 84, in both studies the addition of UMEC to FF/VI resulted in
statistically signiﬁcant and clinically meaningful improvements
versus PBO þ FF/VI (UMEC 62.5 mg þ FF/VI, 0.147e0.153 L;
UMEC 125 mg þ FF/VI, 0.135e0.140 L; all p < 0.001, Table 2;
Fig. 3). Statistically signiﬁcant improvements with UMEC þ FF/VI
versus PBO þ FF/VI were also seen for 0e6 h post-dose WM FEV1
at Days 1 and 28 (p < 0.001, both doses and timepoints in both
studies; Fig. 3).
Both doses of UMEC in addition to FF/VI were associated with
statistically signiﬁcantly greater odds (versus PBO þ FF/VI) of hav-
ing an increase in FEV1 of0.100 L above baseline versus not having
this increase (odds ratio [OR]: UMEC 62.5 mg þ FF/VI, 4.8e5.6;
UMEC 125 mg þ FF/VI, 4.4e5.1; all p < 0.001; Table 2). Improve-
ments versus PBO þ FF/VI were also observed for the proportion of
patients with an FEV1 increase 12% and 0.200 L above baseline
at Day 1, with a statistically signiﬁcant OR for having this increase
(versus not having the increase; OR: UMEC 62.5 mgþ FF/VI, 5.0e6.1;
UMEC 125 mg þ FF/VI, 5.3e6.3; all p < 0.001; Table 2). Serial
FEV1 on Day 1 showed a rapid onset of FEV1 improvements
(statistically signiﬁcantly greater after ~15 min) with both doses
of UMEC þ FF/VI compared with PBO þ FF/VI, which was
maintained at 24 h and through to Day 84 in both studies
(p < 0.001 for all comparisons; Fig. 4). Statistically signiﬁcant
improvements in peak FEV1 at Day 84 were observed withTable 1
Patient demographics and characteristics (ITT population).
Study 1
PBO þ FF/VI
100/25 (N ¼ 206)
UMEC 62.5 þ FF/
100/25 (N ¼ 206
Age, years 64.7 (7.90) 64.9 (8.72)
Sex, n (%)
Male 141 (68) 139 (67)
Current smoker at screeninga, n (%) 90 (44) 81 (39)
Smoking pack-years 50.6 (24.76) 50.1 (24.93)
Baseline (pre-salbutamol) FEV1 (L) 1.156 (0.453) 1.117 (0.453)
Post-salbutamol % predicted FEV1 45.9 (12.95) 44.2 (13.41)
Post-salbutamol FEV1/FVC 48.0 (10.83) 47.8 (10.20)
% reversibility to salbutamol 14.4 (14.36) 14.8 (11.97)
% reversibility to salbutamol and ipratropiumb 20.9 (16.46) 22.6 (14.46)
GOLD stage, n
II, n (%) 82 (40) 82 (40)
III, n (%) 95 (46) 90 (44)
IV, n (%) 29 (14) 34 (17)
Baseline salbutamol use (puffs per day) 2.1 (2.64) 2.4 (2.75)
Baseline CAT score 16.5 (7.49) 16.3 (7.36)
Baseline SGRQ score 44.52 (16.974) 44.48 (17.800)
Reversible to salbutamol, n (%) 60 (29) 58 (28)
Reversible to salbutamol and ipratropiumb, n (%) 97 (47) 108 (53)
Number (%) of patients with one or more COPD exacerbations, in the 12 months prior
Managed without oral/systemic
steroids and/or antibiotics, n (%)
10 (5) 14 (7)
Required oral/systemic steroids,
but not involving hospitalization, n (%)
32 (16) 30 (15)
Requiring hospitalization, n (%) 10 (5) 4 (2)
CAT, COPD Assessment Test; COPD, chronic obstructive pulmonary disease; FEV1, forced
FVC, forced vital capacity; GOLD, Global Initiative for Chronic Obstructive Lung Disease
UMEC, umeclidinium.
Values are reported as mean (standard deviation) unless otherwise stated.
Reversibility was deﬁned as an increase in FEV1 of 12% and 0.200 L following admini
a Reclassiﬁed: patient reclassiﬁed as current smoker if they had smoked within 6 mon
b In Study 1, N¼ 205 in PBOþ FF/VI 100/25, N¼ 205 in UMEC 62.5þ FF/VI 100/25, N¼
in UMEC 62.5 þ FF/VI 100/25, N ¼ 207 in UMEC 125 þ FF/VI 100/25.UMEC þ FF/VI versus PBO þ FF/VI (UMEC 62.5 mg þ FF/VI, 0.154
and 0.156 L; UMEC 125 mg þ FF/VI, 0.140 and 0.146 L; p < 0.001
for the comparison in both studies). Similar results were reported
for trough FVC (all comparisons: p < 0.001; Table 2) and serial
FVC (0.066e0.248 L improvement versus PBO þ FF/VI for both
doses at all timepoints and days; all p < 0.001).
3.2.2. Rescue use
In both studies, patients receiving UMEC þ FF/VI experienced
a greater change from baseline in the proportion of rescue-free
days over Weeks 1e12 (UMEC 62.5 mg þ FF/VI, 6.9e14.2%;
UMEC 125 mg þ FF/VI, 5.9e8.7%) versus PBO þ FF/VI (2.3e3.8%;
Table 2). In Study 1, statistically signiﬁcant reductions in rescue
salbutamol use were observed for both UMEC þ FF/VI groups
versus PBO þ FF/VI (UMEC 62.5 mg þ FF/VI, 0.4 puffs/day
[p < 0.001]; UMEC 125 mgþ FF/VI, 0.2 puffs/day [p < 0.05]; Table 2).
However, in Study 2, statistically signiﬁcant improvements in
rescue-medication use were only observed with UMEC
62.5 mg þ FF/VI (0.3 puffs/day, p < 0.01; Table 2).
3.2.3. HRQoL
Numerical improvements from baseline in CAT scores (where a
negative number denotes an improvement) were observed in all
UMEC þ FF/VI treatment groups (UMEC 62.5 mg þ FF/VI, 1.1
to 0.6; UMEC 125 mg þ FF/VI, 0.5 to 0.1) at Day 84. In both
studies, the PBO þ FF/VI treatment group showed a numerical
deterioration (0.1e0.3) at Day 84.
In Study 1, there were no signiﬁcant differences in SGRQ scores
(where a negative number denotes an improvement) observed
between the treatment arms at Days 28 and 84. In Study 2, patientsStudy 2
VI
)
UMEC 125 þ FF/VI
100/25 (N ¼ 207)
PBO þ FF/VI
100/25 (N ¼ 206)
UMEC 62.5 þ FF/VI
100/25 (N ¼ 206)
UMEC 125 þ FF/VI
100/25 (N ¼ 207)
63.8 (7.65) 62.6 (9.00) 62.6 (8.12) 63.4 (7.49)
127 (61) 125 (61) 135 (66) 131 (63)
87 (42) 119 (58) 120 (58) 116 (56)
47.9 (23.99) 46.2 (25.70) 46.8 (27.01) 45.6 (23.34)
1.158 (0.445) 1.287 (0.465) 1.240 (0.442) 1.271 (0.476)
45.6 (12.84) 47.4 (12.46) 46.3 (12.21) 47.9 (12.75)
49.2 (10.34) 49.0 (10.18) 48.1 (10.31) 48.8 (10.39)
13.8 (11.62) 11.1 (12.75) 13.2 (12.88) 12.1 (11.25)
21.4 (16.09) 16.1 (15.74) 20.7 (16.29) 18.6 (13.26)
84 (41) 94 (46) 99 (48) 103 (50)
99 (48) 85 (41) 86 (42) 83 (40)
24 (12) 27 (13) 21 (10) 21 (10)
2.1 (2.57) 1.7 (2.66) 2.1 (3.16) 1.5 (2.32)
17.0 (7.83) 17.8 (7.34) 17.6 (6.92) 17.4 (7.16)
45.48 (17.174) 42.20 (17.300) 44.14 (16.477) 41.78 (16.302)
58 (28) 51 (25) 65 (32) 64 (31)
103 (50) 81 (39) 107 (52) 106 (51)
to study enrollment
8 (4) 14 (7) 4 (2) 14 (7)
32 (16) 28 (14) 26 (13) 31 (15)
5 (2) 2 (<1) 7 (3) 6 (3)
expiratory volume in one second; FF/VI, ﬂuticasone furoate/vilanterol combination;
; ITT, intent-to-treat; PBO, placebo; SGRQ, St George's Respiratory Questionnaire;
stration of the stated therapeutic agent.
ths prior to screening.
207 in UMEC 125þ FF/VI 100/25; in Study 2, N¼ 206 in PBOþ FF/VI 100/25, N¼ 205
Table 2
Summary of lung function, symptomatic and health-related quality of life endpoints (ITT population).
Study 1 Study 2
PBO þ FF/VI
100/25 (N ¼ 206)
UMEC 62.5 þ FF/VI
100/25 (N ¼ 206)
UMEC 125 þ FF/VI
100/25 (N ¼ 207)
PBO þ FF/VI
100/25 (N ¼ 206)
UMEC 62.5 þ FF/VI
100/25 (N ¼ 206)
UMEC 125 þ FF/VI
100/25 (N ¼ 207)
Trough FEV1 at Day 85, LS mean
change from baseline, L (SE)
n ¼ 190
-0.020 (0.011)
n ¼ 195
0.103 (0.011)
n ¼ 188
0.108 (0.011)
n ¼ 179
-0.030 (0.0110)
n ¼ 195
0.092 (0.011)
n ¼ 199
0.081 (0.011)
Difference vs PBO þ FF/VI 100/25 (95% CI)a e 0.124* (0.093, 0.154) 0.128*(0.098, 0.159) e 0.122* (0.091, 0.152) 0.111* (0.081, 0.141)
0e6 h post-dose WM FEV1 at Day 84,
LS mean change from baseline, L (SE)
n ¼ 191
0.034 (0.012)
n ¼ 195
0.187 (0.012)
n ¼ 189
0.175 (0.012)
n ¼ 180
0.017 (0.012)
n ¼ 195
0.164 (0.012)
n ¼ 199
0.152 (0.011)
Difference vs PBO þ FF/VI 100/25 (95% CI) e 0.153* (0.118, 0.187) 0.140* (0.106, 0.175) e 0.147* (0.114, 0.179) 0.135* (0.103, 0.167)
Proportion of patients with trough
FEV1 0.100 L above baseline at
Day 85, n (%)
n ¼ 205
27 (13)
n ¼ 206
94 (46)
n ¼ 206
89 (43)
n ¼ 205
28 (14)
n ¼ 206
88 (43)
n ¼ 206
84 (41)
Odds ratio vs PBO þ FF/VI 100/25 (95% CI) e 5.6* (3.4, 9.1) 5.1* (3.1, 8.3) e 4.8* (2.9, 7.8) 4.4* (2.7, 7.2)
Proportion of patients with FEV1
increase 12% and 0.200
L above baseline at Day 1, n (%)
n ¼ 205
27 (13)
n ¼ 206
95 (46)
n ¼ 206
98 (48)
n ¼ 205
29 (14)
n ¼ 206
93 (45)
n ¼ 206
95 (46)
Odds ratio vs PBO þ FF/VI 100/25 (95% CI) e 6.1* (3.7, 10.0) 6.3* (3.8, 10.3) e 5.0* (3.1, 8.1) 5.3* (3.2, 8.5)
Peak FEV1 at Day 84, LS mean
change from baseline, L (SE)
n ¼ 192
0.093 (0.013)
n ¼ 196
0.247 (0.013)
n ¼ 189
0.239 (0.013)
n ¼ 180
0.079 (0.012)
n ¼ 195
0.235 (0.012)
n ¼ 199
0.219 (0.012)
Difference vs PBO þ FF/VI 100/25 (95% CI) e 0.154* (0.118, 0.189) 0.146* (0.110, 0.182) e 0.156* (0.122, 0.190) 0.140* (0.107, 0.174)
Trough FVC at Day 85, LS mean
change from baseline, L (SE)
n ¼ 190
-0.051 (0.019)
n ¼ 195
0.148 (0.019)
n ¼ 188
0.132 (0.019)
n ¼ 179
-0.079 (0.018)
n ¼ 195
0.108 (0.018)
n ¼ 199
0.073 (0.017)
Difference vs PBO þ FF/VI 100/25 (95% CI) e 0.199* (0.147, 0.252) 0.183* (0.130, 0.236) e 0.186* (0.137, 0.236) 0.152* (0.103, 0.201)
Rescue salbutamol use, Weeks 1e12b
Change from baseline in the percentage
of rescue-free days, % mean (SD)
3.8 (22.54) 14.2 (26.78) 8.7 (27.30) 2.3 (21.62) 6.9 (23.95) 5.9 (24.49)
Change from baseline rescue salbutamol use, n ¼ 197 n ¼ 198 n ¼ 197 n ¼ 188 n ¼ 196 n ¼ 205
LS mean change puffs/day (SE) 0.3 (0.08) 0.7 (0.08) 0.6 (0.08) 0.1 (0.08) 0.4 (0.08) 0.3 (0.08)
Difference vs PBO þ FF/VI 100/25 (95% CI) e 0.4* 0.2y e 0.3z 0.2
CAT score, Day 84b n ¼ 194 n ¼ 196 n ¼ 190 n ¼ 181 n ¼ 195 n ¼ 202
Mean change from baseline (SD) 0.3 (5.97) 1.1 (5.83) 0.1 (6.14) 0.1 (5.20) 0.6 (4.84) 0.5 (4.65)
SGRQ score, Day 84 n ¼ 200 n ¼ 199 n ¼ 201 n ¼ 180 n ¼ 192 n ¼ 198
LS mean change from baseline (SE) 2.23 (0.699) 3.05 (0.694) 1.77 (0.704) 0.59 (0.607) 1.56 (0.593) 1.04 (0.582)
LS mean change from baseline:
difference vs PBO þ FF/VI 100/25 (95% CI)
e 0.82 (2.76, 1.12) 0.46 (1.49, 2.41) e 2.16y (3.83, 0.49) 1.63 (3.29, 0.02)
SGRQ responderc, n (%) 72 (35) 81 (40) 68 (33) 43 (21) 71 (35) 64 (31)
Odds ratio (column vs
PBO þ FF/VI 100/25; 95% CI)
e 1.20 (0.80, 1.80) 0.90 (0.60, 1.36) e 2.01z (1.28, 3.14) 1.77y (1.12, 2.78)
CAT, COPD Assessment Test; CI, conﬁdence interval; FEV1, forced expiratory volume in 1 s; FF/VI, ﬂuticasone furoate/vilanterol combination; FVC, forced vital capacity; ITT, intent-to-treat; LS, least squares; PBO, placebo;
SD, standard deviation; SE, standard error; SGRQ, St George's Respiratory Questionnaire; UMEC, umeclidinium.
*p  0.001; zp  0.01; yp < 0.05 vs PBO.
Analysis performed using a repeatedmeasures model with covariates of treatment, baseline (mean of the two assessments made 30min and 5min pre-dose on Day 1), smoking status, Day, Day by baseline, and Day by treatment
interactions. The weighted mean was calculated from the pre-dose FEV1 measurements at 15 min, 30 min, 1 h, 3 h and 6 h.
a Values are differences in LS mean (95% CI).
b No formal between-group analyses were planned for these endpoints.
c Response was deﬁned as an SGRQ total score of 4 units below baseline or lower.
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Fig. 2. Least squares mean (95% CI) change from baseline in trough FEV1 (L) (ITT population) in Study 1 (a) and in Study 2 (b). Analysis performed using a repeated measures model
with covariates of treatment, baseline (mean of the two assessments made 30 min and 5 min pre-dose on Day 1), smoking status, Day, Day by baseline and Day by treatment
interactions. CI, conﬁdence interval; FEV1, forced expiratory volume in one second; ITT, intent-to-treat; FF/VI, ﬂuticasone furoate/vilanterol combination; LS, least squares;
UMEC, umeclidinium.
T.M. Siler et al. / Respiratory Medicine 109 (2015) 1155e11631160treated with UMEC 62.5 mg þ FF/VI showed statistically signiﬁcant
improvements in SGRQ score versus PBO þ FF/VI at Day 84 (2.16;
p < 0.05) and also higher odds of being an SGRQ responder (as
deﬁned by a reduction from baseline of 4 units in SGRQ score)
versus being an SGRQ non-responder (OR: 2.01, p < 0.01; Table 2).3.2.4. Safety
The incidence of AEs and serious AEs was similar across treat-
ment groups in both studies (Table 3), with nasopharyngitis,
headache and back pain most commonly reported AEs (Table 3).
Six deaths were reported during both studies, none of which
were considered related to the study treatment. Five deaths were in
the PBO þ FF/VI groups (three due to myocardial infarction; one
due to cardio-respiratory arrest; one due to pneumonia) and one
death was in the UMEC 62.5 mg þ FF/VI group (Study 2; due to
gastric ulcer hemorrhage, atrial ﬁbrillation, cardiogenic shock and
myocardial infarction).
COPD exacerbations were infrequent (8% in any group) in both
studies. In Study 1, the incidence of on-treatment COPD exacerba-
tions varied between groups, with 7% (n ¼ 14) in the
UMEC 125 mg þ FF/VI treatment group, 3% (n ¼ 6) in the
UMEC 62.5 mg þ FF/VI group and 3% (n ¼ 7) in the PBO þ FF/VI
group. In Study 2, the COPD exacerbation incidences were also
infrequent, with 8% (n ¼ 17) in the PBO þ FF/VI group, 3% (n ¼ 6)
in the UMEC 62.5 mg þ FF/VI group and 2% (n ¼ 4) in the
UMEC 125 mg þ FF/VI group.Fig. 3. Least squares mean (95% CI) change from baseline in 0e6 h WM FEV1 (L) (ITT popul
model with covariates of treatment, baseline (mean of the two assessments made 30 min an
interactions. CI, conﬁdence interval; FEV1, forced expiratory volume in one second; FF/V
UMEC, umeclidinium; WM, weighted mean.The incidence of cardiovascular AEs of special interest was low
and similar across all treatment groups in both studies (range:
<1e3% [n ¼ 2e6] across treatment groups); additionally, the in-
cidences of pneumonia and lower respiratory tract infection
excluding pneumoniawere similar across treatment groups (range:
0e1% [n ¼ 0e3] and 0e<1% [n ¼ 0e2], respectively).
No clinically relevant treatment-related changes in vital signs
were reported across any treatment group in either study.4. Discussion
The results of the two randomized, double-blind, placebo-
controlled parallel studies presented here demonstrate that once-
daily UMEC added to once-daily FF/VI (100/25 mg) provides clini-
cally and statistically signiﬁcant improvements in lung function
compared with PBO þ FF/VI in patients with COPD. No substantial
clinical beneﬁt was observed with the UMEC 125 mg dose over the
UMEC 62.5 mg dose when added to FF/VI, which is consistent with
the ﬁndings observed in UMEC monotherapy studies [21e23].
Despite consistent improvements in lung function measured
across both studies, the HRQoL results of the studies were incon-
sistent. This may be reﬂective of aweak correlation between HRQoL
and FEV1, as demonstrated previously [1,24], or may be due to
differences between the patient populations included in the studies
reﬂected in treatment prior to enrollment: percentages of patients
treated with ICS (Study 1 ¼ 63%, Study 2 ¼ 46%) and LAMA (Study
1¼22%, Study 2¼ 46%). The inconsistency could also be related to aation) in Study 1 (a) and in Study 2 (b). Analysis performed using a repeated measures
d 5 min pre-dose on Day 1), smoking status, Day, Day by baseline and Day by treatment
I, ﬂuticasone furoate/vilanterol combination; ITT, intent-to-treat; LS, least squares;
T.M. Siler et al. / Respiratory Medicine 109 (2015) 1155e1163 1161possible improvement in patients' HRQoL during the 4-week run-in
period, during which patients received treatment with FF/VI, [25]
making subsequent improvements more difﬁcult to detect
with these patient-reported outcomes (PRO) instruments. The lack
of signiﬁcant improvement in SGRQ results, despite statistical
improvements in lung function, has also been reported in the
ILLUMINATE study, where the LABA/LAMA combination of
indacaterol/glycopyrronium was compared with the ICS/LABA
combination of ﬂuticasone propionate/salmeterol [26]. While it
is accepted by some investigators that an improvement of
0.100 L in FEV1 is the MCID [15,16,26,27], and that patients can
perceive this difference [16], the inconsistent results between
FEV1 and SGRQ reported in these studies and others [26] suggest
that further studies are needed to better understand the corre-
lation between lung function improvement and improvement in
SGRQ score.
The disparity between FEV1 and SGRQ results in one of the two
studies may also imply that the design of PRO tools and the deﬁned
MCIDsmaywarrant further investigation.While there are generally
accepted MCIDs for SGRQ (improvement of greater than 4 units
from baseline and compared with placebo) [28] and transition
dyspnea index (improvement of greater than 1 unit overall and
compared with placebo) [29], there are no MCIDs reported for
comparisons of active treatments. The available PRO tools appear to
detect differences between placebo and active treatments, but not
necessarily between two (or more) active treatments, for example
in ILLUMINATE [26], or at least at the same MCID as for placebo
comparisons. These points may suggest that the development of
new PRO tools to measure differences between active treatments
are required, however, this remains debated within the literature
[30,31]. As HRQoL remains an important measure of treatmentFig. 4. Serial FEV1 least squares mean change from baseline on Day 1 and Day 84 (L) (ITT pop
model with covariates of treatment, baseline (mean of the two assessments made 30 min
treatment interactions. CI, conﬁdence interval; FEV1, forced expiratory volume in one second;
UMEC, umeclidinium.effectiveness in COPD [32], consensus needs to be reached as to the
most effective way of capturing it within clinical trials.
All treatments were well tolerated, with no notable treatment-
related differences in AEs or changes in vital signs, and COPD ex-
acerbations were infrequent (8% across all each treatment
groups). Overall, the safety proﬁles of both doses of UMEC (62.5 mg
and 125 mg) when added to FF/VI were similar to that previously
reported for FF, VI, or UMEC as monotherapies [22,33e35], or FF/VI
combination therapy [25,33].
COPD exacerbations constitute the greatest proportion of the
total COPD economic burden [1] and as such are an important
consideration in the management of this disease. However, these
studies were not designed to examine the treatment effect of the
addition of UMEC to FF/VI in patients with COPD on the endpoint of
exacerbations, but rather focused on lung function as a ﬁrst step in
determining the efﬁcacy of triple therapy. These studies were only
12 weeks in duration, which is considered a sufﬁcient period of
time to observe sustained effects in lung function. However, longer
studies with a patient population with a history of exacerbations
would be needed to assess the beneﬁt of this triple therapy on
COPD exacerbations compared with ICS/LABA therapy.
There are other limitations that should be considered. Firstly,
concurrent rescue medication was permitted; however, this was
implemented across all study groups, is commonly used in COPD
clinical studies and reﬂects clinical practice [1,7,9]. Secondly, the
studies were not powered to detect differences in AEs, indicating a
possible direction for future studies in this area. In addition, dys-
pnea was not measured in this study, only rescue use, which could
be considered as a surrogate symptomatic outcome. As dyspnea can
have a large impact on the daily lives of patients with COPD [36], it
will be important to establish if the improvement in rescue useulation) in Study 1 (a) and in Study 2 (b). Analysis performed using a repeated measures
and 5 min pre-dose on Day 1), smoking status, time, time by baseline and time by
FF/VI, ﬂuticasone furoate/vilanterol combination; ITT, intent-to-treat; LS, least squares;
Table 3
Summary of on-treatment adverse events (ITT population).
Study 1 Study 2
PBO þ FF/VI
100/25 (N ¼ 206)
UMEC 62.5 þ FF/VI
100/25 (N ¼ 206)
UMEC 125 þ FF/VI
100/25 (N ¼ 207)
PBO þ FF/VI
100/25 (N ¼ 206)
UMEC 62.5 þ FF/VI
100/25 (N ¼ 206)
UMEC 125 þ FF/VI
100/25 (N ¼ 207)
Any on-treatment AE, n (%) 72 (35) 75 (36) 80 (39) 81 (39) 67 (33) 62 (30)
Most common on-treatment AEs
reported by  3% of patients in
any treatment group by study, n (%)
Headache 6 (3) 9 (4) 9 (4) 5 (2) 8 (4) 4 (2)
Nasopharyngitis 7 (3) 7 (3) 10 (5) 22 (11) 11 (5) 19 (9)
Back pain 3 (1) 7 (3) 5 (2) 4 (2) 8 (4) 2 (<1)
Dysgeusia 4 (2) 6 (3) 4 (2) e e e
Cough 1 (<1) 3 (1) 7 (3) e e e
Diarrhea 2 (<1) 6 (3) 2 (<1) e e e
Inﬂuenza 1 (<1) 2 (<1) 6 (3) e e e
Any on-treatment SAEs, n (%) 6 (3) 2 (<1) 8 (4) 11 (5) 8 (4) 3 (1)
Any on-treatment drug-related AEs, n (%) 15 (7) 15 (7) 24 (12) 7 (3) 6 (3) 7 (3)
Any AEs related to permanent
discontinuation of
medication/withdrawal, n (%)
5 (2) 3 (1) 6 (3) 9 (4) 7 (3) 2 (<1)
Fatal AEs, n (%) 1 (<1) 0 0 4 (2) 1 (<1) 0
COPD exacerbation 7 (3) 6 (3) 14 (7) 17 (8) 6 (3) 4 (2)
AEs of special interesta, n (%)
Cardiovascular e any event 6 (3) 5 (2) 3 (1) 6 (3) 2 (<1) 3 (1)
Cardiac arrhythmias 3 (1) 1 (<1) 1 (<1) 2 (<1) 1 (<1) 2 (<1)
Cardiac failure 3 (1) 3 (1) 2 (<1) 0 1 (<1) 1 (<1)
Cardiac ischemia 1 (<1) 1 (<1) 0 3 (1) 2 (<1) 0
Stroke 0 1 (<1) 0 1 (<1) 0 0
Pneumonia and LRTI e any event 5 (2) 2 (<1) 4 (2) 1 (<1) 2 (<1) 3 (1)
LRTI excluding pneumonia 2 (<1) 2 (<1) 1 (<1) 0 0 2 (<1)
Pneumonia 3 (1) 0 3 (1) 1 (<1) 2 (<1) 1 (<1)
AE, adverse event; COPD, chronic obstructive pulmonary disease; FF/VI, ﬂuticasone furoate/vilanterol combination; ITT, intent-to-treat; LRTI, lower respiratory tract infection;
MedDRA, Medical Dictionary for Regulatory Activities; PBO, placebo; SAE, serious adverse event; UMEC, umeclidinium.
a The incidence of AEs of special interest was assessed using standardized MedDRA queries for cardiac arrhythmias, cardiac failure, cardiac ischemia (myocardial infarction,
other ischemic heart disease), stroke (central nervous system hemorrhages and cerebrovascular conditions). Selected preferred terms were used to deﬁne the LRTI excluding
pneumonia and pneumonia AEs of special interest.
T.M. Siler et al. / Respiratory Medicine 109 (2015) 1155e11631162reported with triple therapy can be translated to improvements in
dyspnea.
5. Conclusions
The results from these two randomized, double-blind, clinical
trials demonstrated that the addition of UMEC (62.5 mg and 125 mg)
to FF/VI provides signiﬁcant improvements in lung function
compared with PBO þ FF/VI in patients with COPD. The reported
safety proﬁles were similar across all treatment groups.
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